| Outcome Measures: |
Primary: Percentage change from baseline in triglycerides (TG) at week 12, Baseline, Week 12 | Secondary: Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 12, Week 12|Percentage changes from baseline in apoB/apoA1 ratio at week 12, Baseline, Week 12|Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 12, Baseline, Week 12|Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 12, Baseline, Week 12|Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 12, Baseline, Week 12|Percentage changes from baseline in uric acid at week 12, Baseline, Week 12|Percentage of patients who achieved non-High-Density Lipoprotein-Cholesterol (non-HDL-C) level less than 2,6 mmol/l at week 52, Week 52|Percentage changes from baseline in apoB/apoA1 ratio at week 52, Baseline, Week 52|Percentage changes from baseline in non-High-Density Lipoprotein-Cholesterol (non-HDL-C) at week 52, Baseline, Week 52|Percentage changes from baseline in High-Density Lipoprotein-Cholesterol (HDL-C) at week 52, Baseline, Week 52|Percentage changes from baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) at week 52, Baseline, Week 52|Percentage changes from baseline in uric acid at week 52, Baseline, Week 52 | Other: Number of adverse events (AE) caused discontinuations of investigational products, Up to 52 week
|
